CN107148277B - 一种抑制脂肪细胞分化和胰岛素耐受的药物 - Google Patents

一种抑制脂肪细胞分化和胰岛素耐受的药物 Download PDF

Info

Publication number
CN107148277B
CN107148277B CN201580059881.7A CN201580059881A CN107148277B CN 107148277 B CN107148277 B CN 107148277B CN 201580059881 A CN201580059881 A CN 201580059881A CN 107148277 B CN107148277 B CN 107148277B
Authority
CN
China
Prior art keywords
ser
leu
ala
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580059881.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107148277A (zh
Inventor
罗永章
王慧
李辉
鲁薪安
付彦
占顺利
周代福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CN202210191378.9A priority Critical patent/CN114558111A/zh
Publication of CN107148277A publication Critical patent/CN107148277A/zh
Application granted granted Critical
Publication of CN107148277B publication Critical patent/CN107148277B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580059881.7A 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物 Active CN107148277B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210191378.9A CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410610777 2014-11-03
CN201410610777X 2014-11-03
CN201510021469 2015-01-15
CN2015100214698 2015-01-15
PCT/CN2015/093726 WO2016070798A1 (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210191378.9A Division CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Publications (2)

Publication Number Publication Date
CN107148277A CN107148277A (zh) 2017-09-08
CN107148277B true CN107148277B (zh) 2022-03-22

Family

ID=55908589

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580059881.7A Active CN107148277B (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物
CN202210191378.9A Pending CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210191378.9A Pending CN114558111A (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Country Status (7)

Country Link
US (2) US20180015148A1 (https=)
EP (1) EP3246043A4 (https=)
JP (2) JP2018501195A (https=)
CN (2) CN107148277B (https=)
AU (1) AU2015342324B2 (https=)
CA (1) CA3003760A1 (https=)
WO (1) WO2016070798A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6896636B2 (ja) * 2015-02-13 2021-06-30 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ 組換えタンパク質薬の分子設計
EP3539570B1 (en) 2016-11-10 2022-04-13 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
US10276161B2 (en) 2016-12-27 2019-04-30 Google Llc Contextual hotwords

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306819B1 (en) * 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
AU2002323543A1 (en) * 2001-09-07 2003-03-24 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN101596320B (zh) * 2006-01-20 2013-01-09 清华大学 一种治疗肿瘤的药物及其应用
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用
EP2214709A4 (en) * 2007-11-08 2011-05-11 Univ Utah Res Found USE OF ANGIOGENESIS ANTAGONISTS IN DISEASES WITH ANOMAL VENEER PREPARATION
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
MX2013011294A (es) * 2011-03-30 2014-10-06 Univ Texas Metodos y composiciones para dirigir celulas adiposas en mamiferos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034116A1 (zh) * 2011-09-09 2013-03-14 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective;Sam Virtue等;《Biochim Biophys Acta》;20100106;第1801卷(第3期);第339页左栏倒数第3段、第340页左栏第3-4段 *
Angiogenesis in chronic liver disease and its complications;Stephanie Coulon等;《Liver Int》;20101115;第31卷(第2期);第146页左栏第1段、右栏第2段、第153页左栏第1段、最后1段、第156页左栏第2段 *

Also Published As

Publication number Publication date
US20180015148A1 (en) 2018-01-18
WO2016070798A1 (zh) 2016-05-12
EP3246043A4 (en) 2018-09-05
JP2018501195A (ja) 2018-01-18
CN107148277A (zh) 2017-09-08
CA3003760A1 (en) 2016-05-12
AU2015342324B2 (en) 2021-08-19
EP3246043A9 (en) 2018-03-14
US20220409703A1 (en) 2022-12-29
CN114558111A (zh) 2022-05-31
EP3246043A1 (en) 2017-11-22
AU2015342324A1 (en) 2017-06-29
JP2020172546A (ja) 2020-10-22
JP7227197B2 (ja) 2023-02-21

Similar Documents

Publication Publication Date Title
US20220409703A1 (en) Drug for inhibiting adipose cell differentiation and insulin resistance
Xiao et al. Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction
EP2940035B1 (en) Polypeptides, nucleic acid molecule encoding polypeptides, and uses of polypeptides
CN110511267B (zh) 抗肥胖多肽、组合物及其应用和用于治疗肥胖症的药物
CN106459152A (zh) 具有抗肥胖及抗糖尿病功效的肽及其的用途
WO2016197592A1 (zh) 一种长链非编码rna hnf1a-as1在制备治疗人体恶性实体瘤药物中的应用
CN108348563A (zh) 含有紫草根提取物作为有效成分的用于预防、改善或治疗周围神经病变的组合物
JP2016044172A (ja) ポリペプチドを含有する生体内で多くの効果を有する医薬組成物及びその用途
EP3398949B1 (en) Uses of compound in preparation of drugs for treating brain glioma
CN113501870A (zh) 一种乳源多肽及其嵌合肽在用于制备促进脂肪细胞能量代谢药物中的应用
JPWO2008050789A1 (ja) インターロイキン１１の心疾患治療薬としての利用
CN119013405A (zh) 包含utr的核酸构建体及其应用
Yoon et al. Cyclophilin B, a molecule chaperone, promotes adipogenesis in 3T3-L1 preadipocytes via AKT/mTOR pathway
CN110592222A (zh) Triml1作为肝癌的分子标记物的应用
Yang et al. Pigment epithelium-derived factor improves TNFα-induced hepatic steatosis in grass carp (Ctenopharyngodon idella)
CN105596458A (zh) 金芪降糖片治疗糖尿病心血管并发症
CN111808186B (zh) 一种人源性分泌型fndc5蛋白及其制备方法和用途
CN101190944A (zh) 人类新细胞因子及其用途
CN104511028B (zh) Klf9基因在抑制肝癌中的应用
CN107961382B (zh) miR-1252在制备治疗特应性皮炎的药物中的应用
CN120789268B (zh) Aldh1a2抑制剂和检测aldh1a2或ra的试剂的应用
Chen et al. Knockdown of Galectin-3 confers myocardial protection against ischemia-reperfusion injury, modulating oxidative stress, inflammatory response, and the peroxisome proliferator-activated receptor g signaling pathway
US8216562B2 (en) Inhibiting non-hematopoietic cancer with interleukin 6
CN116478995A (zh) 用于治疗糖尿病心肌病的小核酸分子
CN118987018A (zh) 环状rna或其过表达试剂在制备预防和/或治疗心脏病产品中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant